Research Study

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN)
Principal Investigator 
Sean Barbour

Overview

Body Locations and Systems 
Kidney Disease
ClinicalTrials.gov# 
NCT03608033
Status 
Recruiting
Study Start/End 
Sep 5, 2019 to Dec 31, 2024
Locations 
Diamond Health Care Centre, St. Paul's Hospital
Name/Title 
Zainab Sheriff, Research Coordinator
Phone 
604-682-2344 ext.64744
Purpose of Study 

The purpose of this study is to evaluate the safety and efficacy of OMS721 in patients with IgA nephropathy. The study will assess proteinuria by 24-hour urine protein excretion (UPE) in g/day at 36 weeks from beginning of treatment.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.